Skip to main content

Volume 20 Supplement 1

Availability of quality-assured medical abortion medicines

Research

Publication of this supplement was funded by the UNDP–UNFPA–UNICEF–WHO–World Bank Special Programme of Research, Development and Research Training in Human Reproduction, a cosponsored programme executed by the WHO. The articles have undergone the journal's standard peer review process for supplements. The Supplement Editor declares that they have no competing interests.

Edited by Friday Okonofua.


  1. Availability of quality-assured medical abortion medicines plays a crucial role in providing comprehensive abortion care. However, access to these medicines is still restricted for many abortion seekers. Incre...

    Authors: Ulrika Rehnström Loi, Ndola Prata, Amy Grossman, Antonella Lavelanet, Natalie Williams and Bela Ganatra
    Citation: Reproductive Health 2023 20(Suppl 1):20
  2. In recent years a growing number of manufacturers and medical abortion products have entered country markets and health systems, with varying degrees of quality and accessibility. An interplay of factors inclu...

    Authors: Amy Grossman, Ndola Prata, Natalie Williams, Bela Ganatra, Antonella Lavelanet, Laurence Läser, Chilanga Asmani, Hayfa Elamin, Leopold Ouedraogo, Md. Mahmudur Rahman, Musu Julie Conneh-Duworko, Bentoe Zoogley Tehoungue, Harriet Chanza, Henry Phiri, Bharat Bhattarai, Narayan Prasad Dhakal…
    Citation: Reproductive Health 2023 20(Suppl 1):58

    The Correction to this article has been published in Reproductive Health 2023 20:160

  3. In 2019, the World Health Organization identified improving access to safe abortion as an important priority toward improving sexual and reproductive health and rights and achieving Sustainable Development Goa...

    Authors: Meera Thapa Upadhyay, Terence Fusire, Ulrika Rehnström Loi, Annik Sorhaindo, Mohammed Salahuddin, Mohammed Ayub Hossain, Tashi Tshomo, Erna Mulati, Lovely Daisy, Dian Putri Anggraweni, Tumiur Gultom, Fitri Indrawati, Mariyam Jenyfa, Myint Myint Than, Bharat Bhattarai, Loshan Moonasinghe…
    Citation: Reproductive Health 2024 20(Suppl 1):191
  4. Despite their importance in reducing maternal mortality, information on access to Mifepristone, Misoprostol, and contraceptive medicines in the Eastern Mediterranean Region is limited.

    Authors: Mohamed Afifi, Nilmini Hemachandra, Qais Sikandar, Rana Hajjeh, Ulrika Rehnström Loi, Laurence Läser, Dima Qato, Zahir Sidiqui Abdul, Paata Chikvaidze, Raghad Abdul Redha Abbas, Khalid Al-Kinani, Hanan Hasan, Faysal El-Kak, Alissar Rady, Omelkheir Brngali, Mohamed Hashem…
    Citation: Reproductive Health 2024 20(Suppl 1):192
  5. Medical abortion with mifepristone and misoprostol can be provided up to 63 days’ gestation in India. This accounts for 67.5 percent of all abortions in the country. We conducted an assessment to determine the...

    Authors: Priya Karna, K. Aparna Sharma, Amy Grossman, Madhur Gupta, Tapas Chatterjee, Natalie Williams, Ndola Prata, Annik Sorhaindo, Laurence Läser, Ulrika Rehnström Loi, Bela Ganatra and Pushpa Chaudhary
    Citation: Reproductive Health 2024 20(Suppl 1):193

Annual Journal Metrics

  • 2022 Citation Impact
    3.4 - 2-year Impact Factor
    4.2 - 5-year Impact Factor
    1.657 - SNIP (Source Normalized Impact per Paper)
    1.093 - SJR (SCImago Journal Rank)

    2023 Speed
    18 days submission to first editorial decision for all manuscripts (Median)
    166 days submission to accept (Median)

    2023 Usage 
    3,031,937 downloads
    1,524 Altmetric mentions

Reaction to the 2024 Alabama Supreme Court ruling on IVF

Read the blog by Gwendolyn P. Quinn & Laura Kimberly on the Alabama Supreme Court ruling on IVF and what it means for women with cancer.

Engaging with African feminist interpretations of the Maternal

Read the blog by Ogochukwu Udenigwe on interpretations of motherhood and its relationship with patriarchal culture among African feminists.